Drug companies to pay Hawaii USD 700 million to settle Plavix blood thinner lawsuit
Live Events
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
Pharmaceutical companies have agreed to pay Hawaii USD 700 million to settle its lawsuit over the efficacy and safety of the blood thinner Plavix, the state attorney general's office has announced. A court ruling last year ordered Bristol Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi to pay a combined USD 916 million.But before an appeal was decided, a settlement was reached for the lower amount, the attorney general's office said.In a joint statement on Friday, the companies said they "are pleased to resolve this litigation, and to continue their companies' focus on discovering, developing, and delivering innovative medicines to patients.""Plavix has helped millions of people with cardiovascular disease around the world for nearly 30 years and it continues to be endorsed as a first-line therapy by leading treatment guidelines across the globe," the statement added.First Circuit Court Judge James Ashford found that there was a risk that about 30 per cent of patients, particularly non-Caucasians, might have a "diminished response" to Plavix but the companies did not update their labels, Attorney General Anne Lopez said last year.Neither company has admitted wrongdoing.Governor Josh Green called it a "landmark settlement" and a "major victory" for the state.The settlement divides the USD 700 million equally between Bristol Myers Squibb and Sanofi, with the funds to be paid by wire transfer by June 9, the attorney general's office said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 hours ago
- Economic Times
More Nova Scotians are dying from the Flu than COVID; here's what the data shows
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Influenza has now overtaken COVID-19 as the leading cause of respiratory-related deaths in Nova Scotia this season, the first time this has happened since the pandemic began. According to the province's latest respiratory watch report, 124 people have died from influenza so far during the 2024–25 respiratory season. In comparison, COVID-19 has been linked to 108 deaths in the same current respiratory season began on August 25, 2024, and runs until August 29, 2025. Health officials say this shift highlights changing patterns in virus transmission and immunity. Experts warn that the flu is now a far bigger threat to public health disease specialists say the trend reflects strong vaccine uptake and natural immunity against COVID‑19. She added that while COVID‑19 deaths are declining, the flu is year's influenza activity began early. Confirmed flu cases climbed through late winter and spring. Hospital admissions from influenza have increased significantly. Clinics and hospitals are now seeing more flu‑related complications than COVID‑19 COVID‑19, influenza has not attracted the same public concern. Mask mandates and testing protocols are no longer in place, which, according to health officials, may be contributing to the rapid vaccines are still available in Nova Scotia. Health providers strongly recommend them for all residents. They emphasize immunizing older adults, young children, and people with chronic health conditions, as these groups remain most at risk for severe flu boosters are also available. However, uptake has slowed, especially among younger and low‑risk groups. This may explain why COVID‑19 deaths remain stable, even as cases continue at a low but steady Scotia's health authorities are now focused on public education. They stress that both flu and COVID‑19 vaccines are essential. Officials are urging residents to stay home if unwell and to maintain good capacity is becoming a concern again. Bed occupancy and emergency visits have risen with the flu wave. Health officials warn that the system could be stretched if the flu season provincial government plans to track flu and COVID‑19 data closely and update policy based on case trends and hospital pressure, and no new restrictions are planned at this time.
Economic Times
2 hours ago
- Economic Times
Auto sector seeks government action on China rare earth magnet imports
(You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The automobile industry has sought government support in expediting approvals from the Chinese government for importing rare earth magnets used in various applications, including passenger per the industry sources, various domestic suppliers have already sought approval from the Chinese government through their local vendors in no approvals have been granted so far, sources said. China controls over 90 per cent of global processing capacity for the magnets, used across multiple sectors including automobiles, home appliances and clean Chinese government has put restrictions, with effect from April 4, mandating special export licences for seven rare earth elements and related magnets.
Mint
4 hours ago
- Mint
Diderot's Curse and the BNPL Trap: Why India's middle class may be walking into a debt crisis
In 1769, French philosopher Denis Diderot received a luxurious scarlet dressing gown. At first, it delighted him. But then he noticed that everything around it—his old chair, desk, and rug—seemed shabby in comparison. One by one, he replaced them until he was mired in debt. This story, known as the 'Diderot Effect," remains a parable for how one act of consumption can trigger a cascade of financial decisions, often with ruinous outcomes. Fast forward to modern India, where a digital version of this effect is taking shape. This time, it's not scarlet robes but smartphones, kitchen renovations, weekend getaways, and online shopping sprees—all made seemingly affordable by Buy Now, Pay Later (BNPL) apps and instant small loans. These easy credit tools promise convenience and inclusion, especially to millennials and Gen Z professionals eager to live aspirational lives. Yet, behind the glitter of financial empowerment lies a troubling spiral of overleveraging, especially for India's burgeoning middle class, which lacks the structural safety nets that cushion such risks in the West. The growth numbers are staggering. According to CRIF High Mark data, personal loans of ₹10,000- ₹50,000 value grew at an annualised rate of 19% for the 2021-2024 period. BNPL offerings by fintech firms like LazyPay, ZestMoney (now defunct), and Paytm Postpaid have exploded in reach. But this rapid expansion masks a darker reality: a growing chunk of borrowers are falling behind on payments. Also Read: ITR 2025: Sahaj or Sugam — Which is the right income tax form for you? RBI's Financial Stability Report Dec 2024 shows that 11% of the borrowers originating a personal loan under ₹50,000 had an overdue personal loan, and over 60% of them had taken out more than three loans during 2024-25 so far. Moreover, nearly three-fifths of customers who took out a personal loan in Q2: 2024-25 had more than three live loans at the time of origination. Loan delinquency TransUnion Cibil reports show that the rising delinquency rates for BNPL products rose to 4.8% from 3.6% within a year. Most of these defaults are concentrated among borrowers under 30—a demographic already grappling with underemployment, wage stagnation, and high rental costs in cities. Unlike traditional credit cards or personal loans, BNPLs often fly under the radar. They don't always show up in credit reports immediately, and multiple platforms can extend concurrent credit to the same borrower without any central visibility. This creates a dangerous illusion of affordability. A consumer may think they're paying only ₹2,000 per month on a new iPhone—but when stacked with deferred payments on furniture, groceries, vacations, and even tuition, the monthly outflow quietly balloons. This trend becomes even more alarming when paired with India's lack of universal healthcare and weak social protection. A 2022 report by Azim Premji University found that 68% of middle-class households had no health insurance, and over half would fall into poverty if faced with a major hospitalisation. In this vacuum, medical BNPL has emerged as a fast-growing segment, with platforms like QubeHealth and SaveIn offering deferred payment options at clinics and hospitals. For a family already juggling four EMIs, a sudden ₹60,000 emergency loan for surgery can push them into a tailspin. Also Read: RBI repo rate cut: How home loan EMI, and bank FD return will change? EXPLAINED The regulatory response has so far been cautious but piecemeal. RBI has cracked down on unregulated digital lending apps and discouraged pre-approved credit lines without user consent. But BNPL providers—many operating through NBFC partnerships—still operate in a regulatory grey area. With no unified reporting framework and lax income verification, users can easily borrow beyond their repayment capacity. The illusion of financial empowerment masks a systemic failure to track and contain household debt. Moving ahead So, what's the way forward? Structural fixes like universal healthcare, formal job creation, and large-scale financial literacy are imperative, but they take time. What India needs right now is a set of practical, near-term interventions, both by consumers and regulators, to curb the looming crisis. On the consumer side, individuals must begin treating BNPL for what it is: a form of unsecured debt, not a lifestyle hack. Before clicking 'pay later," users should track their cumulative EMIs across platforms using credit aggregator tools like OneScore or CRED. A good rule of thumb is to ensure no more than 30% of monthly income is locked into repayments. Stacking credit across apps may feel manageable initially, but when salaries are delayed or unexpected expenses arise, this house of cards collapses swiftly. Regulators, too, must move decisively. The RBI should mandate real-time reporting of BNPL loans to credit bureaus and enforce a central dashboard where consumers can view all liabilities. Income-based eligibility limits—particularly for first-time or subprime borrowers—must be imposed to prevent overleveraging. Most urgently, coercive collection practices—already on the rise via WhatsApp threats and public shaming—must be met with heavy penalties. Also Read: Health insurance vs medical corpus: What should senior citizens prioritize? India's middle class today is not buying goods—it's buying identities, dreams, and status symbols in instalments. But as Diderot discovered, the cost of one indulgence can quickly multiply when there are no checks. If we don't build those guardrails now, a generation of Indians may find themselves trapped, dressed in aspiration, and drowning in debt. Kiran J Mahasuar is assistant professor, co-chairperson – Strategy, Innovation & Entrepreneurship Area, IMT Ghaziabad
